Literature DB >> 1330938

Decreased expression of E-cadherin and increased invasive capacity in EBV-LMP-transfected human epithelial and murine adenocarcinoma cells.

R Fåhraeus1, W Chen, P Trivedi, G Klein, B Obrink.   

Abstract

The EBV-encoded membrane protein LMP is one of 9 viral proteins regularly expressed in virally immortalized B lymphocytes. It is expressed in EBV-carrying lymphoblastoid cell lines of normal origin and in the majority of the poorly differentiated nasopharyngeal carcinomas, but not in Burkitt lymphomas. LMP has been reported to transform rodent fibroblasts, to inhibit epithelial differentiation and to alter morphology and cytokeratin expression in an in vitro immortalized human keratinocyte cell-line, RHEK-I. We now report that an LMP-transfected mouse mammary carcinoma line, SHG, exhibits a similar morphological change to that previously described in the LMP-transfected RHEK-I. In the LMP-transfected RHEK-I and SHG cells, we observed a decreased expression of the calcium-dependent adhesion molecule E-cadherin. The LMP-transfected RHEK-I cells were capable of invading type-I collagen gels while the control cells were not. The LMP-transfected SHG cells showed a significantly higher invasive capacity than the original cell line.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1330938     DOI: 10.1002/ijc.2910520527

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases.

Authors:  Chi-Neu Tsai; Chia-Lung Tsai; Ka-Po Tse; Hwan-You Chang; Yu-Sun Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-10       Impact factor: 11.205

2.  Epstein-Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK-MAPK pathway.

Authors:  Christopher W Dawson; Louise Laverick; Mhairi A Morris; Giorgos Tramoutanis; Lawrence S Young
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

3.  Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein-Barr virus-triggered B cell proliferation.

Authors:  Shu-Chun Tsai; Sue-Jane Lin; Cheau-Jye Lin; Ya-Ching Chou; Jiun-Han Lin; Te-Huei Yeh; Mei-Ru Chen; Li-Min Huang; Meng-You Lu; Ya-Chi Huang; Huan-Yun Chen; Ching-Hwa Tsai
Journal:  J Virol       Date:  2013-06-12       Impact factor: 5.103

4.  The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1.

Authors:  T Yoshizaki; H Sato; M Furukawa; J S Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

Review 5.  The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  Chi Man Tsang; Sai Wah Tsao
Journal:  Virol Sin       Date:  2015-04-21       Impact factor: 4.327

6.  Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein.

Authors:  Joanna Laurson; Sadaf Khan; Rachel Chung; Karen Cross; Kenneth Raj
Journal:  Carcinogenesis       Date:  2010-02-01       Impact factor: 4.944

7.  EBV latent membrane protein 1 effects on plakoglobin, cell growth, and migration.

Authors:  Kathy H Y Shair; Caroline I Schnegg; Nancy Raab-Traub
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

Review 8.  Prognostic factors for bladder cancer.

Authors:  T Otto; M Goepel; K H Heider; H Rübben
Journal:  Urol Res       Date:  1995

9.  Response to cAMP levels of the Epstein-Barr virus EBNA2-inducible LMP1 oncogene and EBNA2 inhibition of a PP1-like activity.

Authors:  R Fåhraeus; L Palmqvist; A Nerdstedt; S Farzad; L Rymo; S Laín
Journal:  EMBO J       Date:  1994-12-15       Impact factor: 11.598

10.  Co-expression of low-risk HPV E6/E7 and EBV LMP-1 leads to precancerous lesions by DNA damage.

Authors:  Karina Uehara; Yasuka Tanabe; Shintaro Hirota; Saki Higa; Zensei Toyoda; Kiyoto Kurima; Shinichiro Kina; Toshiyuki Nakasone; Akira Arasaki; Takao Kinjo
Journal:  BMC Cancer       Date:  2021-06-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.